The James P. Allison Institute at The University of Texas MD Anderson Cancer Center, Houston, recently announced the establishment of its scientific advisory board to provide strategic guidance and evaluation of its research portfolio and programs. The 11-person advisory board will be co-chaired by Robert Schreiber, PhD, the Andrew M. and Jane M. Bursky Distinguished Professor of Pathology and Immunology at Washington University School of Medicine, St. Louis, and Elaine Mardis, PhD, Co-Executive Director of the Steve and Cindy Rasmussen Institute for Genomic Medicine at Nationwide Children’s Hospital and Professor of Pediatrics at The Ohio State University College of Medicine, Columbus.
The Allison Institute was launched to foster groundbreaking scientific research that will integrate immunobiology across disciplines. The institute is led by Director James P. Allison, PhD, Regental Chair of Immunology, together with Padmanee Sharma, MD, PhD, Director of Scientific Programs for the Institute and Professor of Genitourinary Medical Oncology and Immunology at MD Anderson, and Director of Operations Raghu Kalluri, MD, PhD, Chair of Cancer Biology at MD Anderson.
Members of the scientific advisory board include:
- Mark Dawson, MD, PhD, clinician-scientist and Associate Director of the Peter MacCallum Cancer Centre, Melbourne, Australia. Dr. Dawson also is Professor at the University of Melbourne, the Sir Edward Dunlop Fellow for the Cancer Council of Victoria, and a Howard Hughes Medical Institute International Research Scholar.
- Philip Greenberg, MD, Professor and Head of the Program in Immunology and Rona Jaffe Foundation Endowed Chair at Fred Hutchinson Cancer Center, Seattle
- Marcia Haigis, PhD, Professor of Cell Biology and Director of Gender Equity for Faculty in Science at Harvard Medical School, Boston
- Diane Mathis, PhD, Professor of Immunology at Harvard Medical School and Morton Grove-Rasmussen Chair of Immunohematology
- Miriam Merad, MD, PhD, Director of the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai and Director of the Human Immune Monitoring Center at Mount Sinai, New York
- Kunle Odunsi, MD, PhD, Director of the University of Chicago Medicine Comprehensive Cancer Center and Dean for Oncology, Biological Services Division at the University of Chicago
- Phillip Sharp, PhD, Institute Professor at the Massachusetts Institute of Technology (MIT), Boston, and a member of the Department of Biology at the Koch Institute for Integrative Cancer Research at MIT
- Karen Vousden, PhD, Group Leader at the Francis Crick Institute, London, and former Chief Scientist for Cancer Research UK
- Catherine J. Wu, MD, leader of the Division of Stem Cell Transplantation and Cellular Therapies at Dana-Farber Cancer Institute, Boston.
